Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PMDA to Invite Reviewers, Inspectors from Asian Countries
June 14, 2010
- GSK, Yoshitomi to Terminate Copromotion of Paxil in July
June 14, 2010
- Otsuka Completes New Basic Research Facility
June 14, 2010
- Japan-China to Strengthen Partnership in Clinical Trials
June 14, 2010
- NBI to Establish Holding Company
June 14, 2010
- CROee Ties Up with BBK for Recruitment of Subjects
June 14, 2010
- Industry Expects New Gov't Will Retain Industrial Policy
June 14, 2010
- Japanese Drugs Regarded as Reliable in China: Mr Matsubara
June 14, 2010
- Avastin Effective for Ovarian Cancer: ASCO 2010
June 14, 2010
- Gov't to Intensively Invest in Selected Fields
June 14, 2010
- Merger with Wyeth Puts Pfizer Closer to Top Place in Japan
June 14, 2010
- Tsumura: Record-High Profits Driven by Kampo Medicines
June 14, 2010
- Eribulin Prolongs OS in Breast Cancer Patients: ASCO
June 14, 2010
- METI's Council Calls For 5% Reduction in Corporate Tax
June 14, 2010
- Sales of 23 Domestic JPMA Member Companies Up 4.3%
June 14, 2010
- Nissui Pharm.: Profits Up Due to Profit Structure Reform
June 14, 2010
- Terumo: Sales Up 4.4% to ¥316 Bil.
June 14, 2010
- FDA Accepts NDA for Eisai's AcipHex Extended-Release
June 14, 2010
- Sales of 26 Member Companies Up 2.0%: JPMA
June 14, 2010
- Biofermin: Sales Down 1.0% to ¥8,455 Mil.
June 14, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…